KemPharm is a pharmaceutical company in the US that develops superior prodrug versions of existing drugs using its Ligand Activated Therapy technology to cure severe medical conditions including ADHD, stimulant use disorder, and CNS rare diseases such as idiopathic hypersomnia. The company's lead product candidate is KP1077 (serdexmethylphenidate), which is in Phase II clinical trials for the treatment of IH and narcolepsy. They have developed prodrug candidates like KP879 for the treatment of stimulant use disorder, which is under Phase I clinical trials.